Answers are grounded in this paper and cite their sources.
Preclinical evaluation demonstrates enhanced antimetastatic activity and macrophage stimulation by vizantin in melanoma models, indicating strong potential for clinical immunotherapy.
Vizantin, 6,6'-bis-O-(3-nonyldodecanoyl)-α,α'-trehalose, was developed as a safe immunostimulator on the basis of a structure-activity relationship (SAR) study with trehalose 6,6'-dicorynomycolate (TDCM). It was possible to synthesize vizantin on a large scale more easily than in the case of TDCM, and the compound exhibited more potent prophylactic effect on experimental lung metastasis of B16-F0 melanoma cells. Because vizantin stimulated human macrophages, it is a promising candidate for clinical application.
No takes yet. Share an insight, caveat, or question.
Yamamoto et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: